(Q44124158)

30 November 2017

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma (English)

1 reference

30 November 2017

0 references

Danai D Daliani

1

1 reference

30 November 2017

Christos N Papandreou

2

1 reference

30 November 2017

Peter F Thall

3

1 reference

30 November 2017

Xuemei Wang

4

1 reference

30 November 2017

Cherie Perez

5

1 reference

30 November 2017

Rose Oliva

6

1 reference

30 November 2017

Lance Pagliaro

7

1 reference

30 November 2017

Robert Amato

8

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

30 November 2017

1 reference

30 November 2017

95

1 reference

30 November 2017

758-765

1 reference

30 November 2017

4

1 reference

Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects

30 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Thalidomide: current and potential clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Phase II trial of thalidomide for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

Activity of thalidomide in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Pharmacokinetics of thalidomide in an elderly prostate cancer population

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10740

7 January 2021

Identifiers

DOI

10.1002/CNCR.10740

1 reference

30 November 2017

1 reference